Research Article| Volume 47, ISSUE 17, P2493-2511, November 2011

Rare cancers are not so rare: The rare cancer burden in Europe

Published:October 28, 2011DOI:



      Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Cancers in Europe (RARECARE) provides estimates of the incidence, prevalence and survival of rare cancers in Europe based on a new and comprehensive list of these diseases.

      Materials and methods

      RARECARE analysed population-based cancer registry (CR) data on European patients diagnosed from 1988 to 2002, with vital status information available up to 31st December 2003 (latest date for which most CRs had verified data). The mean population covered was about 162,000,000. Cancer incidence and survival rates for 1995–2002 and prevalence at 1st January 2003 were estimated.


      Based on the RARECARE definition (incidence <6/100,000/year), the estimated annual incidence rate of all rare cancers in Europe was about 108 per 100,000, corresponding to 541,000 new diagnoses annually or 22% of all cancer diagnoses. Five-year relative survival was on average worse for rare cancers (47%) than common cancers (65%). About 4,300,000 patients are living today in the European Union with a diagnosis of a rare cancer, 24% of the total cancer prevalence.


      Our estimates of the rare cancer burden in Europe provide the first indication of the size of the public health problem due to these diseases and constitute a useful base for further research. Centres of excellence for rare cancers or groups of rare cancers could provide the necessary organisational structure and critical mass for carrying out clinical trials and developing alternative approaches to clinical experimentation for these cancers.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. European parliament and council of the European communities. Decision no. 1295/1999/EC of the European parliament and of the council of 29 April 1999 adopting a programme of community action on rare diseases within the framework for action in the field of public health (1999–2003); 1999.

      2. Available from: [accessed 11.12.09].

        • Greenlee R.T.
        • Goodman M.T.
        • Lynch C.F.
        • et al.
        The occurrence of rare cancers in US adults, 1995–2004.
        Public Health Rep. 2010; 125: 28-43
      3. No Authors listed. Very rare cancers – a problem neglected. Lancet Oncol 2001;2(4):189.

        • Pritchard-Jones K.
        • Kaatsch P.
        • Steliarova-Foucher E.
        • Stiller C.A.
        • Coebergh J.W.
        Cancer in children and adolescents in Europe: developments over 20 years and future challenges.
        Eur J Cancer. 2006; 42: 2183-2190
        • Tan S.B.
        • Dear K.B.
        • Bruzzi P.
        • et al.
        Strategy for randomised clinical trials in rare cancers.
        BMJ. 2003; 327: 47-49
        • De Angelis R.
        • Francisci S.
        • Baili P.
        • et al.
        The EUROCARE-4 database on cancer survival in Europe: data standardization, quality control and methods of statistical analysis.
        Eur J Cancer. 2009; 45: 909-930
      4. Ferlay J, Burkhard C, Whelan S, et al. Check and conversion programs for Cancer Registries. Lyon, France: International Agency for Research on Cancer, Technical Report No. 42; 2005. Available from:

        • Percy C.
        • Fritz A.
        • Jack A.
        • et al.
        International classification of diseases for the oncology (ICD-O).
        3rd ed. World Health Organisation, 2000
        • Capocaccia R.
        • Colonna M.
        • Corazziari I.
        • et al.
        Measuring cancer prevalence in Europe: the EUROPREVAL Project.
        Ann Oncol. 2002; 13: 831-839
        • Capocaccia R.
        • De Angelis R.
        Estimating the completeness of prevalence based on cancer registry data.
        Stat Med. 1997; 16: 425-440
        • Hakulinen T.
        Cancer survival corrected for heterogeneity in patient withdrawal.
        Biometrics. 1982; 38: 933-942
      5. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5, version 2.0. Lyon: IARCPress; 2004.

      6. Available from: [accessed 19.04.11].

        • Terracini B.
        • Coebergh J.W.
        • Gatta G.
        • et al.
        Childhood cancer survival in Europe: an overview.
        Eur J Cancer. 2001; 37: 810-816
      7. Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities, 22.1.2000.